Genomic Context and TP53 Allele Frequency Define Prognostic Subgroups and Response Outcomes in TP53 Mutated Myelodysplastic Syndromes

Authors

Guillermo Montalban-Bravo, University of Texas MD Anderson Cancer Center
Rashmi Kanagal-Shamanna, University of Texas MD Anderson Cancer Center
Christopher Benton, University of Texas MD Anderson Cancer Center
Caleb Class, University of Texas MD Anderson Cancer Center
Kelly Chien, University of Texas MD Anderson Cancer Center
Koji Sasaki, University of Texas MD Anderson Cancer Center
Kiran Naqvi, University of Texas MD Anderson Cancer Center
Yesid Alvarado, University of Texas MD Anderson Cancer Center
Tapan Kadia, University of Texas MD Anderson Cancer Center
Farhad Ravandi, University of Texas MD Anderson Cancer Center
Jorge Cortes, University of Texas MD Anderson Cancer Center
Naval Daver, University of Texas MD Anderson Cancer Center
Koichi Takahashi, University of Texas MD Anderson Cancer Center
Courtney DiNardo, University of Texas MD Anderson Cancer Center
Elias Jabbour, University of Texas MD Anderson Cancer Center
Gautam Borthakur, University of Texas MD Anderson Cancer Center
Naveen Pemmaraju, University of Texas MD Anderson Cancer Center
Marina Konopleva, University of Texas MD Anderson Cancer Center
Sherry Pierce, University of Texas MD Anderson Cancer Center
Carlos Bueso-Ramos, University of Texas MD Anderson Cancer Center
Michael Andreeff, University of Texas MD Anderson Cancer Center
Keyur Patel, University of Texas MD Anderson Cancer Center
Hagop Kantarjian, University of Texas MD Anderson Cancer Center
Guillermo Garcia-Manero, University of Texas MD Anderson Cancer Center

Document Type

Article

Publication Date

November 2019

Publication Title

Blood

First Page

1711

Last Page

1711

DOI

10.1182/BLOOD-2019-124978

Share

COinS